Personalis
MapKure, Personalis Partner to Screen Patients for BRAF Inhibitor Trial
Personalis plans to develop a companion diagnostic to MapKure's BRAF inhibitor, BGB-3245, once biomarkers have been identified in the study.
Quidel Stock Plunges in February as GenomeWeb Index Falls 3 Percent
The GenomeWeb Index underperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index last month.
The company recently announced a deal with personalized ctDNA testing firm Natera and will now follow that with the launch of its own MRD product this year.
Personalis Q4 Revenues up 11 Percent
The genomics company reported revenues of $20.2 million for the quarter, driven by growth in its pharmaceutical services business and other non-VA customers.
Natera, Personalis Team up for Cancer Treatment Monitoring, MRD Testing
Under the non-exclusive deal, Natera will use matched tumor and normal exome sequencing data from Personalis to validate the design of its Signatera ctDNA assays.
Jan 27, 2021
Personalis Prices $150M Public Stock Offering
Jan 12, 2021
Personalis Projects 2020 Q4 Revenues Up 11 Percent
Dec 23, 2020
Nov 5, 2020
Personalis Q3 Revenues Up 16 Percent
Aug 12, 2020
Personalis Prices $125M Public Stock Offering
Aug 6, 2020
Personalis Q2 Revenues Up 23 Percent
May 7, 2020
Personalis Q1 Revenues Up 36 Percent
Apr 24, 2020
Nov 15, 2019